ARCHIVES

LDK378 Demonstrates 58 Percent Overall Response Rate in Phase I

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

Study of Dlurectic Use As Renal Cell Cancer Risk Gets Concept Approval

March 10, 1989

In Brief: Tipping Resigns Forom ACS; Vaughan Joins UAB BMT Program; PCI Recruits Ball, Finn, Mirro

September 20, 1991

New Biomarker Findings Show Improvement in KRAS Subtype In Phase III Erbitux Trial

May 30, 2014

FDA Clears Rapid Test For Aspergillus Infection

May 30, 2003

Dose Adjustments Of Other Drugs Questioned; Underdosing Or Overdosing?

October 15, 2010

How Elite Institutions Were Affected By A Decade of Constricted Funding

October 31, 2014